Thu, January 19, 2023
Wed, January 18, 2023
Tue, January 17, 2023
Mon, January 16, 2023
Sat, January 14, 2023
Fri, January 13, 2023
Thu, January 12, 2023

Joseph Schwartz Maintained (ASND) at Buy with Increased Target to $163 on, Jan 17th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-increased-target-to-163-on-jan-17th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Joseph Schwartz of SVB Leerink, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $148 to $163 on, Jan 17th, 2023.

Joseph has made no other calls on ASND in the last 4 months.



There are 6 other peers that have a rating on ASND. Out of the 6 peers that are also analyzing ASND, 0 agree with Joseph's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Joseph


  • Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $177 on, Tuesday, January 3rd, 2023
  • Vikram Purohit of "Morgan Stanley" Maintained at Buy with Increased Target to $148 on, Tuesday, November 15th, 2022
  • Andreas Argyrides of "Wedbush" Maintained at Buy with Increased Target to $164 on, Monday, November 14th, 2022
  • David Lebowitz of "Citigroup" Maintained at Strong Buy with Increased Target to $163 on, Thursday, November 3rd, 2022
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Increased Target to $130 on, Thursday, November 3rd, 2022
  • Paul Choi of "Goldman Sachs" Initiated at Strong Buy and Held Target at $174 on, Thursday, October 20th, 2022

Publication Contributing Sources